X4 Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XFOR Nasdaq 2830 www.x4pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for X4 Pharmaceuticals, Inc.

Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Dec 8th, 2025 4:04 am
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Nov 24th, 2025 1:07 am
WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies - Nov 18th, 2025 8:39 am
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference - Nov 5th, 2025 2:01 pm
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Nov 5th, 2025 8:00 am
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 6:15 am
Techne (TECH) Meets Q1 Earnings Estimates - Nov 5th, 2025 5:40 am
X4 Pharmaceuticals: Q3 Earnings Snapshot - Nov 5th, 2025 5:22 am
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 5th, 2025 5:00 am
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million - Oct 27th, 2025 5:05 pm
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering - Oct 23rd, 2025 10:37 pm
X4 Pharmaceuticals Announces Proposed Underwritten Public Offering - Oct 23rd, 2025 2:01 pm
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? - Oct 22nd, 2025 10:00 am
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - Sep 29th, 2025 5:30 am
How Analyst Sentiment on X4 Pharmaceuticals Is Shifting After Recapitalization and Leadership Changes - Sep 27th, 2025 7:24 am
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation - Sep 17th, 2025 5:00 am
Sitryx appoints Adam Mostafa as Chief Financial Officer - Sep 8th, 2025 5:00 am
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 15th, 2025 2:05 pm
BC-Most Active Stocks - Aug 13th, 2025 8:30 am
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement - Aug 13th, 2025 5:00 am